q3 earnings per share $129.96.
sees fy non-gaap revenue growth 12% to 13% versus prior guidance of 10% to 10.5%.
q3 sales $747 million versus refinitiv ibes estimate of $647.3 million.
q3 non-gaap earnings per share $3.71.
sees fy covid-related sales $240 million to $245 million.
qtrly sales rose 13.8 percent on a currency neutral basis to $13.8 billion.
q3 operating income $156.8 million versus refinitiv ibes estimate of $144.6 million.
q3 sales $373.5 million versus refinitiv ibes estimate of $324.9 million.
q3 sales $372.2 million versus refinitiv ibes estimate of $326.5 million.
q3 non-gaap gross margin of 57.9% versus 57.5% in q3 of 2020.
q3 research and development expense of $64.5 million, or 8.6% of sales.
q3 sales rose 28.9 percent to $216.2 million.
sees fy non-gaap gross margin in range of 57.5% to 57.8%.
q3 sales rose 4.1 percent to $4.1 billion.
sees fy adjusted ebitda margin in range of 23.5% to 24%.
sees q3 revenue $2.5 billion to $3 billion.
